Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01637623 · ClinicalTrials.gov registry record · Phase 2

Study of Cardiovascular Disease and Obstructive Sleep Apnea

A Phase 2 study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 2
Development phase
87
Enrollment target

NCT01637623: Completed Phase 2 study, sponsored by University of Wisconsin, Madison.

NCT01637623 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01637623, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 2
Development phase
87 participants
Enrollment target

Study Summary

The purpose of this study is to determine if two medicines (allopurinol and losartan) can influence heart and blood vessel health compared to placebo in patients with sleep apnea who are using continuous positive airway pressure (CPAP).

Primary Outcome

The primary outcome variable is the change in the individual slope of the MSNA - SaO2 response curve at 6 weeks and baseline between treatment groups.

Interventions

  • DRUG Placebo
  • DRUG Losartan
  • DRUG Allopurinol

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2012-06
Est. Completion 2015-06
Phase Phase 2
University of Wisconsin, Madison

1,039 total trials

What the finished NCT01637623 record still lists

NCT01637623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01637623 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01637623 about?

NCT01637623 is a clinical study titled "Study of Cardiovascular Disease and Obstructive Sleep Apnea". The purpose of this study is to determine if two medicines (allopurinol and losartan) can influence heart and blood vessel health compared to placebo in patients with sleep apnea who are using continuous positive airway pressure (CPAP).

What is the current status of trial NCT01637623?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2012-06. Estimated completion is 2015-06.

What interventions are being tested in trial NCT01637623?

The interventions under investigation include: Placebo (DRUG), Losartan (DRUG), Allopurinol (DRUG).

Who is sponsoring clinical trial NCT01637623?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01637623's enrollment target sits among peer trials

87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01637623, the US trial registry maintained by the National Library of Medicine. NCT01637623 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.